Biodyne Co

Biodyne Co EBIT Margin

The EBIT Margin (Operating Margin) of Biodyne Co (314930.KQ) as of Nov 3, 2026 is 9.28 %. In the previous year, EBIT Margin (Operating Margin) was -32.82 % — a change of -128.28% (higher).

EBIT Margin

9.28 %

YoY

-128.28%

Last updated:

EBIT Margin (Operating Margin) of Biodyne Co is 2025 9.28 % . EBIT Margin (Operating Margin) of Biodyne Co was 2024 -32.82 % . It decreases by -128.28% higher compared to the previous year.

For Biodyne Co, the operating (EBIT) margin of 9.3% is up versus -62.2% a few years ago.

The Biodyne Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
9.23 KRW
Jan 1, 2019
-41.52 KRW
Jan 1, 2020
-49.75 KRW
Jan 1, 2021
-62.25 KRW
Jan 1, 2022
54.73 KRW
Jan 1, 2023
-50.16 KRW
Jan 1, 2024
-32.82 KRW
Jan 1, 2025
9.28 KRW
The Biodyne Co EBIT Margin history
YEAREBIT MarginYoY
9.28 %-128.28%
-32.82 %-34.58%
-50.16 %-191.64%
54.73 %-187.93%
-62.25 %+25.12%
-49.75 %+19.83%
-41.52 %-549.96%
9.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

EBIT Margin (Operating Margin) of Biodyne Co is 9.28 % in 2025.

EBIT Margin (Operating Margin) of Biodyne Co changed from -32.82 % to 9.28 %, representing a -128.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Biodyne Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biodyne Co

All Key Metrics — Biodyne Co